JNJ-87704916

AXP000092.1 · Oncolytic virus

Platform
HSV-1
Originator
Johnson & Johnson
Sponsor
Johnson & Johnson

Names

NameTypeSource
JNJ-87704916preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
conditionally replicating
Modifications
not disclosed
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C205181

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06311578A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid TumorsRecruitingPhase 12024-04-102028-11-08126Neoplasms

Recent changes

No changes recorded in its trials yet.

Notes

Oncolytic HSV-1 in a phase 1 intratumoral study alone and with cetrelimab (NCT06311578, recruiting). Construct details not disclosed.

How to cite

JNJ-87704916 (AXP000092.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000092.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.